The “Artificial Intelligence in Epidemiology Market by AI Type, Infrastructure, Deployment Model, and Services 2021 – 2026” report has been added to ResearchAndMarkets.com’s offering.
This global AI epidemiology and public health market report provides a comprehensive evaluation of the positive impact that AI technology will produce with respect to healthcare informatics, and public healthcare management, and epidemiology analysis and response. The report assesses the macro factors affecting the market and the resulting need for hardware and software technology used in the public healthcare and epidemiology informatics.
The macro factors include the growth drivers and challenges of the market along with the potential application and usage areas in public health industry verticals. The report also provides the anticipated market value of AI in the public health and epidemiology informatics market globally and regionally. This includes core technology and AI-specific technologies. Market forecasts cover the period of 2021 – 2026.
The Center for Disease Control and Prevention sees epidemiology as the study and analysis of the distribution, patterns and determinants of health and disease conditions in defined populations. It is a cornerstone of public health and shapes policy decisions and evidence-based practice by identifying risk factors for disease and targets for preventive healthcare.
This includes identification of the factors involved with diseases transmitted by food and water, acquired during travel or recreational activities, bloodborne and sexually transmitted diseases, and nosocomial infections such as hospital-acquired illnesses. Epidemiology is also concerned with the identification of trends and predictive capabilities to prevent diseases.
Sources of disease data include medical claims data (commercial claims, Medicare), electronic healthcare records (EHR) including medical treatment facilities and pharmacies, death registries and socioeconomic data. It is important to note that some data is highly structured whereas other data elements are highly unstructured, such as data gathered from social media and Web scraping.
Story continues
Artificial Intelligence (AI) will increasingly be relied upon to improve the efficiency and effectiveness of transforming data correlation to meaningful insights and information. For example, machine learning has been used to gather Web search and location data as a means of identifying potential unsafe areas, such as restaurants involved in food-borne illnesses.
The combination of data aggregation from multiple sources with machine learning and advanced analytics will greatly improve the efficacy of epidemiology predictive models. For example, machine learning allows epidemiologists to evaluate as many variables as desired without increasing statistical error, a problem that often arises with multiple testing bias, which is a condition that occurs when each additional test run on the data increases the possibility for error against a hypothetical target result.
Another example of AI in epidemiology is the use of natural language processing to capture clinical notes for preservation in EHR databases. As part of data capture and identification of most important information, AI will also be used to validate key terms to identify conditions, diagnoses and exposures that are otherwise difficult to capture/identify through traditional data source mining. This will be used for data discovery and validation as well as knowledge representation.
An extremely important and high growth area for AI in epidemiology is drug discovery, safety, and risk analysis, which we anticipate will be a $699 million global market by 2026. Other high opportunity areas for AI are disease and syndromic surveillance, infection prediction and forecasting, monitoring population and incidence of disease, and use of AI in Immunization Information Systems (IIS). In addition to mapping vaccinations to disease incidence, the IIS will leverage AI to identify the impact of public sentiment analysis and for public safety services such as mass notification.
Select Report Findings:
The total global AI in the epidemiology market will reach USD $9.7 billion by 2026
Machine learning in the epidemiology market will reach USD $1.2 billion by 2026
Related to vaccine R&D, AI in drug discovery and risk analysis will reach $699 million by 2026
AI will support various disease-related public health and safety services such as mass notification
EHR databases will be the foundation, but AI will leverage many sources for disease-related data aggregation
Epidemiologic predictive models will be dramatically improved through advanced data analytics and various AI tools and techniques
AI improves the efficiency and effectiveness of transforming healthcare data correlation to meaningful disease insights and information
Report Benefits:
Identify opportunities to leverage AI for drug discovery, disease control, and prevention
Understand the role and importance of various AI technologies in epidemiologic science
Recognize the growing importance of AI in public health in light of the COVID-19 pandemic
Identify leading companies involved in epidemiologic R&D and leveraging AI for optimization
Understand how the use of AI in disease control will shape public policy including data capture
Recognize the importance of merging public and private data and the role of unstructured data
Identify opportunities for AI infrastructure and services in epidemiologic science and technology
Key Topics Covered:
1.0 Executive Summary
2.0 Introduction
3.0 Technology and Application Analysis
4.0 Company Analysis
5.0 Market Analysis and Forecasts 2021 – 2026
6.0 Conclusions and Recommendations
Companies Mentioned
Abbott Informatics
AdvancedMD
Agilent Technologies
Allscripts Healthcare
Athenahealth
Autoscribe Informatics
Cerner Corporation
Change Healthcare
Cognizant
CPSI
CureMD Healthcare
e-Mds Inc.
eClinicalWorks
Epic Systems
GE Healthcare
Google
Graphcore
Greenway Health
IBM
Intel
InterSystems
Kareo
Medhost
Meditech
Medtronic
Micron Technology
Microsoft
NextGen Healthcare
Nvidia
Optum Inc.
Philips Healthcare
For more information about this report visit https://www.researchandmarkets.com/r/bwvnfe
View source version on businesswire.com: https://www.businesswire.com/news/home/20210128005734/en/
Contacts
ResearchAndMarkets.comLaura Wood, Senior Press [email protected] For E.S.T Office Hours Call 1-917-300-0470For U.S./CAN Toll Free Call 1-800-526-8630For GMT Office Hours Call +353-1-416-8900
Source: https://finance.yahoo.com/news/artificial-intelligence-epidemiology-market-ai-151900219.html
